Image

Global Hematopoietic Stem Cell Transplantation Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hematopoietic Stem Cell Transplantation Market, By Type (Allogeneic HSCT, Autologous HSCT, Others), Indication (Congenital Metabolic Defects, Hemoglobinopathies, Myelodysplastic Syndrome, Myeloproliferative Syndromes,  Multiple Sclerosis, Lymphoma, Immune-Deficiency Illnesses, Others),  Application (Bone Marrow Stem Cells, Peripheral Blood Stem Cells, Umbilical Cord Stem Cells, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Hematopoietic Stem Cell Transplantation Market

Market Analysis and Size

In recent years, the Hematopoietic stem cell transplantation market is anticipated to grow rapidly during the forecast period. In 2018, the global incidence of leukaemia was expected to be 437,033 new cases and almost 309,006 deaths, according to the GLOBOCAN 2018 study. According to the World Health Organization (WHO), more than 2000 cord blood hematopoietic stem cell transplants are conducted each year, according to the World Health Organization (WHO). The bone marrow and blood contain hematopoietic stem cells (HSCs). Hematopoietic progenitor cells are another name for them (HPCs). Hematopoietic stem cells can produce platelets, white blood cells, and red blood cells, among other blood cells. These cells are utilized to rebuild or replace a patient's hematopoietic system in the treatment of malignant (such as lymphoma and leukaemia) and non-malignant (including bone marrow failure and hemoglobinopathies) disorders.

Data Bridge Market Research analyses that the Hematopoietic stem cell transplantation market was valued at USD 2,337.43 million in 2021 and is expected to reach USD 5,664.54 million by 2029, registering a CAGR of 11.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Hematopoietic stem cell transplantation (HSCT) is a treatment option for different cancer types and other diseases. Blood stem cells and bone marrow stem cells are both sources of stem cells. Young or immature blood cells present in bone marrow are known as hematopoietic stem cells. Only a small percentage of these blood cells mature in the bone marrow and make it into the bloodstream. Peripheral blood stem cells are the cells that enter the bloodstream. Hematopoietic stem cell transplantation replaces absent, sick, or injured hematopoietic stem cells with healthy hematopoietic stem cells as a result of chemotherapy or radiation.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Allogeneic HSCT, Autologous HSCT, Others), Indication (Congenital Metabolic Defects, Hemoglobinopathies, Myelodysplastic Syndrome, Myeloproliferative Syndromes,  Multiple Sclerosis, Lymphoma, Immune-Deficiency Illnesses, Others),  Application (Bone Marrow Stem Cells, Peripheral Blood Stem Cells, Umbilical Cord Stem Cells, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Otsuka America Pharmaceutical, Inc. (US), Akari Therapeutics, Plc (US), Merck KGaA (Germany), Takeda Pharmaceutical Company Limited (Japan), Lonza (Switzerland), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Pfizer Inc. (US), Sanofi (France), FUJIFILM Holdings Corporation (Japan), bluebird bio, Inc. (US), Pluristem Therapeutics Inc. (Israel), Regen Biopharma Inc. (US), Kiadis Pharma (Netherlands), Taiga Biotechnologies, Inc. (US), CellGenix GmbH (Germany), Escape Therapeutics, Inc. (US), Marker Therapeutics, Inc. (US), Talaris Therapeutics (US)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Hematopoietic Stem Cell Transplantation Market Dynamics

Drivers

  • Rising prevalence of leukemia and lymphoma

The rising prevalence of leukemia and lymphoma is estimated to enhance the growth of the Hematopoietic stem cell transplantation market. According to the Leukemia and Lymphoma Society's 2019 report, 176,200 people in the United States were diagnosed with leukaemia, lymphoma, or myeloma, and 1,399,180 people lived with lymph leukaemia, and myeloma. The rising incidence rate is likely to fuel demand for hematopoietic stem cell transplantation (HSCT), moving the HSCT market forward.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of hematopoietic stem cell transplantation market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get hematopoietic stem cell transplantation, further estimated to enhance the market's growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hematopoietic stem cell transplantation market. Additionally, the rising level of disposable income and increasing incidences of autoimmune disorders will expand hematopoietic stem cell transplantation market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hematopoietic stem cell transplantation market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the hematopoietic stem cell transplantation market growth during the forecast period.

Restraints/Challenges

On the other hand, high-cost associated with the stem cell transplantation will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hematopoietic stem cell transplantation market. Additionally, the lack of donor for the stem cells and low awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This hematopoietic stem cell transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematopoietic stem cell transplantation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hematopoietic stem cell transplantation market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hematopoietic Stem Cell Transplantation Market

Over the projected period, the hematopoietic stem cell transplantation market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the hematopoietic stem cell transplantation market.

Global Hematopoietic Stem Cell Transplantation Market Scope

The hematopoietic stem cell transplantation market is segmented on the basis of type, indication, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Congenital Metabolic Defects
  • Hemoglobinopathies
  • Myelodysplastic Syndrome
  • Myeloproliferative Syndromes,
  • Multiple Sclerosis
  • Lymphoma
  • Immune-Deficiency Illnesses
  • Others

Application

  • Bone Marrow Stem Cells
  • Peripheral Blood Stem Cells
  • Umbilical Cord Stem Cells
  • Others

Type

  • Allogeneic HSCT
  • Autologous HSCT
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Hematopoietic Stem Cell Transplantation Market Regional Analysis/Insights

The hematopoietic stem cell transplantation market is analysed and market size insights and trends are provided by country, type, indication, application, end-users and distribution channel as referenced above.

The countries covered in the hematopoietic stem cell transplantation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hematopoietic stem cell transplantation market because of the increase in the success rate of transplants and rising healthcare expenditure in this region. Additionally, the presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period during the forecast period of 2022 to 2029 due to rising prevalence of blood cancer disorders and surging number of generic manufacturers in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hematopoietic Stem Cell Transplantation Market Share Analysis

The hematopoietic stem cell transplantation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hematopoietic stem cell transplantation market.

Some of the major players operating in the hematopoietic stem cell transplantation market are:

  • Otsuka America Pharmaceutical, Inc. (US)
  • Akari Therapeutics, Plc (US)
  • Merck KGaA (Germany)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Lonza (Switzerland)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (US)
  • Pfizer Inc. (US)
  • Sanofi (France)
  • FUJIFILM Holdings Corporation (Japan)
  • bluebird bio, Inc. (US)
  • Pluristem Therapeutics Inc. (Israel)
  • Regen Biopharma Inc. (US)
  • Kiadis Pharma (Netherlands)
  • Taiga Biotechnologies, Inc. (US)
  • CellGenix GmbH (Germany)
  • Escape Therapeutics, Inc. (US)
  • Marker Therapeutics, Inc. (US)
  • Talaris Therapeutics (US)


SKU-
Why Choose Us


Frequently Asked Questions

The market value for Hematopoietic Stem Cell Transplantation Market is expected USD 5,664.54 million by 2029.
The Hematopoietic Stem Cell Transplantation Market is to grow at a CAGR of 11.70% during the forecast by 2029.
The expansion of the Global Hematopoietic Stem Cell Transplantation Market will be fueled by the increasing incidences of autoimmune disorders and rising prevalence of leukemia and lymphoma. Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global hematopoietic stem cell transplantation market.
The major players operating in the Hematopoietic Stem Cell Transplantation Market are Otsuka America Pharmaceutical, Inc. (US), Akari Therapeutics, Plc (US), Merck KGaA (Germany), Takeda Pharmaceutical Company Limited (Japan), Lonza (Switzerland), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Pfizer Inc. (US), Sanofi (France), FUJIFILM Holdings Corporation (Japan), bluebird bio, Inc. (US), Pluristem Therapeutics Inc. (Israel), Regen Biopharma Inc. (US), Kiadis Pharma (Netherlands), Taiga Biotechnologies, Inc. (US), CellGenix GmbH (Germany), Escape Therapeutics, Inc. (US), Marker Therapeutics, Inc. (US), Talaris Therapeutics (US).